doi: 10.1016/j.bmcl.2006.08.090.
Epub 2006 Sep 20.
New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis
Affiliations
- PMID: 16987658
- DOI: 10.1016/j.bmcl.2006.08.090
Item in Clipboard
New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis
Bioorg Med Chem Lett.
.
Abstract
The synthesis, structure, and biological evaluation of a series of novel rifamycin derivatives, Rifastures (RFA) with potent anti-tuberculosis activity are presented. Some of these derivatives showed higher in vitro activity than rifabutin and rifampicin against not only Mycobacterium tuberculosis strains but also against MAC and Mycobacterium kansasii.
Similar articles
-
In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.Clin Microbiol Infect. 2004 Jul;10(7):662-5. doi: 10.1111/j.1469-0691.2004.00917.x. Clin Microbiol Infect. 2004. PMID: 15214882
-
Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.Bioorg Med Chem. 2009 Jan 15;17(2):503-11. doi: 10.1016/j.bmc.2008.12.006. Epub 2008 Dec 10. Bioorg Med Chem. 2009. PMID: 19119013
-
[In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex].Kekkaku. 1990 Dec;65(12):805-10. Kekkaku. 1990. PMID: 2127615 Japanese.
-
[In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].Kekkaku. 1999 Jan;74(1):63-70. Kekkaku. 1999. PMID: 10067057 Review. Japanese.
-
Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.Arch Immunol Ther Exp (Warsz). 2000;48(3):183-8. Arch Immunol Ther Exp (Warsz). 2000. PMID: 10912623 Review.
Cited by
-
Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.EcoSal Plus. 2020 Apr;9(1):10.1128/ecosalplus.ESP-0017-2019. doi: 10.1128/ecosalplus.ESP-0017-2019. EcoSal Plus. 2020. PMID: 32342856 Free PMC article.
-
Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy.Polymers (Basel). 2018 Jun 8;10(6):636. doi: 10.3390/polym10060636. Polymers (Basel). 2018. PMID: 30966670 Free PMC article.
-
Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms.J Antibiot (Tokyo). 2020 Dec;73(12):868-872. doi: 10.1038/s41429-020-0346-x. Epub 2020 Jul 10. J Antibiot (Tokyo). 2020. PMID: 32651464 Free PMC article.
-
Inhalable Antitubercular Therapy Mediated by Locust Bean Gum Microparticles.Molecules. 2016 May 28;21(6):702. doi: 10.3390/molecules21060702. Molecules. 2016. PMID: 27240337 Free PMC article.
-
Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo.Arch Toxicol. 2024 Aug;98(8):2541-2556. doi: 10.1007/s00204-024-03763-w. Epub 2024 May 7. Arch Toxicol. 2024. PMID: 38713375
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
